Novo Nordisk has experienced a 50% drop due to potential tariffs and recent clinical trial results. Read why I rate NVO stock a strong buy right now.

Pharma giant Novo Nordisk, which makes the obesity drug Wegovy, says the widespread availability of copycat medications is hurting its sales.

GEMMA Collins has today revealed the horrifyingly cruel nickname she was called before going on fat jabs. The TV favourite, ...

A total of 29 new blockbuster-in-waiting drugs entered the late-stage pipeline in 2024, a jump from the previous year’s 19.

Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the ...

Schumer said she was having success on Mounjaro after previously being unable to "handle" Ozempic's side effects.

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

German business-software group SAP claimed the top spot as Europe's largest company by market value, dethroning Danish pharmaceutical company Novo Nordisk.

The FDA ordered compounding pharmacies to stop making copycat versions of weight loss drugs like Ozempic and Zepbound now ...

The exorbitant costs of drugs like Wegovy — especially compared to other countries — have prompted some insurers to tighten ...

GLP-1 drugs such as Wegovy, Ozempic, Zepbound and Mounjaro have helped millions of people combat type 2 diabetes and ...

By screening people for eating disorders and disordered eating before these medications are prescribed, we can prevent unintended consequences.